A testing strategy to evaluate the mutagenic activity of industrial chemicals in cultured mammalian cells.

A. Li

DOI: https://doi.org/10.1016/0273-2300(85)90035-2

1985-06-01

Abstract:

What problem does this paper attempt to address?

Activation of P53 Promotes Renal Injury in Acute Aristolochic Acid Nephropathy.

Li Zhou,Ping Fu,Xiao R. Huang,Fei Liu,Kar Neng Lai,Hui Y. Lan

DOI: https://doi.org/10.1681/asn.2008111133

IF: 14.978

2010-01-01

Journal of the American Society of Nephrology

Abstract:Ingestion of aristolochic acid (AA) can cause AA nephropathy (AAN), in which excessive death of tubular epithelial cells (TECs) characterize the acute phase. AA forms adducts with DNA, which may lead to TEC apoptosis via p53-mediated signaling. We tested this hypothesis both by studying p53-deficient mice and by blocking p53 in TECs with its inhibitor pifithrin-alpha. AA induced acute AAN in wild-type mice, resulting in massive apoptotic and necrotic TEC death and acute renal failure; p53 deficiency or pharmacologic inhibition attenuated this injury. In vitro, AA induced apoptotic and necrotic death of TEC in a time- and dosage-dependent manner, with apoptosis marked by a 10-fold increase in cleaved caspase-3 and terminal deoxynucleotidyl transferase-mediated digoxigenin-deoxyuridine nick-end labeling-positive/Annexin V-positive propidium iodide-negative TECs (all P < 0.001). AA induced dephosphorylation of STAT3 and the subsequent activation of p53 and TEC apoptosis. In contrast, overexpression of STAT3, p53 inhibition, or p53 knockdown with small interfering RNA all attenuated AA-induced TEC apoptosis. Taken together, these results suggest that AA induces TEC death via apoptosis by dephosphorylation of STAT3 and posttranslational activation of p53, supporting the hypothesis that p53 promotes renal injury in acute AAN.
The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53(+/+), Trp53(+/-) and Trp53(-/-) mice

Annette M Krais,Ewoud N Speksnijder,Joost P M Melis,Radek Indra,Michaela Moserova,Roger W Godschalk,Frederik-J van Schooten,Albrecht Seidel,Klaus Kopka,Heinz H Schmeiser,Marie Stiborova,David H Phillips,Mirjam Luijten,Volker M Arlt

DOI: https://doi.org/10.1007/s00204-015-1531-8

Abstract:The tumour suppressor p53 is one of the most important cancer genes. Previous findings have shown that p53 expression can influence DNA adduct formation of the environmental carcinogen benzo[a]pyrene (BaP) in human cells, indicating a role for p53 in the cytochrome P450 (CYP) 1A1-mediated biotransformation of BaP in vitro. We investigated the potential role of p53 in xenobiotic metabolism in vivo by treating Trp53(+/+), Trp53(+/-) and Trp53(-/-) mice with BaP. BaP-DNA adduct levels, as measured by (32)P-postlabelling analysis, were significantly higher in liver and kidney of Trp53(-/-) mice than of Trp53(+/+) mice. Complementarily, significantly higher amounts of BaP metabolites were also formed ex vivo in hepatic microsomes from BaP-pretreated Trp53(-/-) mice. Bypass of the need for metabolic activation by treating mice with BaP-7,8-dihydrodiol-9,10-epoxide resulted in similar adduct levels in liver and kidney in all mouse lines, confirming that the influence of p53 is on the biotransformation of the parent compound. Higher BaP-DNA adduct levels in the livers of Trp53(-/-) mice correlated with higher CYP1A protein levels and increased CYP1A enzyme activity in these animals. Our study demonstrates a role for p53 in the metabolism of BaP in vivo, confirming previous in vitro results on a novel role for p53 in CYP1A1-mediated BaP metabolism. However, our results also suggest that the mechanisms involved in the altered expression and activity of the CYP1A1 enzyme by p53 in vitro and in vivo are different.
Study on DNA Damage Induced by Aristolochic Acid in Vitro

LI Hai-shan,CHEN Xin-zhi,ZHONG Lai-fu

DOI: https://doi.org/10.3969/j.issn.1002-3127.2005.04.014

2005-01-01

Journal of Toxicology

Abstract:Objective To study the DNA damage induced by aristolochic acid(AA) in vitro.Methods In cultured human embryonic kidney cell lines 293 and ERCC1-XPF-293 transfected with nucleotide excision repair genes,cytotoxicity difference between them induced by AA with methyl thiazolyl tetrazolium(MTT) test was performed.With single cell gel electrophoresis assay the DNA single strand breaks induced by AA in 293 cells were observed.To probe the DNA cross-links induced by AA and its metabolic activation in calf thymus DNA,EB fluorescence assay was used.Results There was significant difference in IC_(50) values between AA treated 293 cells and ERCC1-XPF-293 cells(480.1 and 661.8 μ mol/L,respectively,P0.05).AA above 60 μmol/L induced DNA single strand breaks.The DNA cross-links were observed when S9-mix were added,while which could be decreased by added α-naphthoflavone,an inhibitor of CYP1A.Conclusion DNA damage induced by AA plays an important role in its cytotoxicity.
Agglutination with con A dependent on cell cycle.

L. Smets

DOI: https://doi.org/10.1038/NEWBIO245113A0

1973-09-26

Abstract:
Aristolochic acid I induce DNA damage and cell cycle arrest in proximal tubule epithelium cell

李瑛,刘志红,郭啸华,苏健,陈朝红,周虹,黎磊石

DOI: https://doi.org/10.3969/j.issn.1006-298X.2004.01.002

2004-01-01

Abstract:Objective: Aristolochic acid I (AAI) has been proved responsible for the acellular tubulointerstitial damage in Chinese herb nephropathy and carcinogenic property in rodents. The mechanism has been seldom probed into so far. In this study, porcine proximal tubule epithelial cells (LLC-PK1) were used to examine AAI associated DNA damage and cell cycle arrest with respect to the involvement of P53 pathway activation. Methodology: LLC-PK1 cells were treated by adding AAI at different concentrations (80, 160, 320, 640 and 1280ng/ml) for 24 hours and a control group was set up. DNA damage and cell cycle arrest of LLC-PK1 cells were examined by single-cell gel electrophoresis (or comet assay) and flow cytometry (FCM). Expression of P53 protein in LLC-PK1 cells was detected with immunofluorescence staining and FCM. Results: DNA damage was not detected in control cells and LLC-PK1 cells treated with AAI (80ng/ml) by using comet assay. However, comet assay was positive ( with the appearance of a tail of damaged DNA migrating away from the nucleus) in LLC-PK1 cells exposed to AAI (160~1280ng/ml). A dose-dependant effect of AAI was detected by measuring the tail length, the ratio of tail length to full length, and the tail fluorescence intensity in these groups(P0.01). Necrosis and apoptosis were not found in LLC-PK1 cells treated with the range of AAI dosage (160~1280ng/ml). By using FCM, the percentage of cells in G2/M phase increased markedly and dose- dependantly in AAI treated (160-1280ng/ml) LLC-PK1 cells (P0.05 or P0.01). No difference was found between the treatment groups and the control group in the expression of P53 protein by detecting the intensity of immunofluorescence staining and mean fluorescence (P0.05 ). Conclusions: For cultured LLC-PK1 cells, AAI treatment can induce DNA damage and cell cycle arrest in G2/M phase in a dose-dependant manner. These effects of AAI in LLC-PK1 cells shed light on the mechanism of acellular and irreversible injury in tubulointerstitium of AAI nephropathy, and oncogenicity in urinary tract in AAI treated rodents.
Aristolochic Acid I-induced DNA Damage and Cell Cycle Arrest in Renal Tubular Epithelial Cells in Vitro

Ying Li,Zhihong Liu,Xiaohua Guo,Jian Shu,Zhaohong Chen,Leishi Li

DOI: https://doi.org/10.1007/s00204-006-0090-4

2006-01-01

Archives of Toxicology

Abstract:DNA damage is a critical event preceding cellular apoptosis or necrosis. This study was carried out to investigate the effect of aristolochic acid I (AAI) on DNA damage and cell cycle in porcine proximal tubular epithelial cell lines (LLC-PK1 cells). LLC-PK1 cells were stimulated with AAI at the concentrations of 80, 320, and 1,280 ng/ml for 24 h. DNA damage was examined by comet assay and the cell cycle was assayed by flow cytometry (FCM), cellular apoptosis and lysis were examined simultaneously. Cellular nuclear changes were observed by electron microscopy and the expression of wild-type p53 protein and mRNA were measured by FCM and RT-PCR. We found that AAI-induced DNA damage prior to apoptosis and lysis in LLC-PK1 cells in a dose-dependent manner (P<0.01). The percentage of cells in the G2/M phase that were treated with AAI (320 and 1,280 ng/ml) for 24 h increased significantly (P<0.01). Electron micrographs showed the nuclear abnormalities in AAI-treated cells. The expression of p53 protein and mRNA did not change in the AAI-treated cells. AAI may cause DNA damage and cell cycle arrest in LLC-PK1 cells through a wild-type p53-independent pathway, prior to apoptosis or necrosis. This study on the molecular mechanism of AAI-induced toxicity may explain why tubular epithelial cells present limited proliferation and regeneration abilities in the clinical presentation of AAI-associated nephrotoxicity.
Hepatic Premalignant Alterations Triggered by Human Nephrotoxin Aristolochic Acid I in Canines

Ke Jin,Kun-kai Su,Tong Li,Xia-qing Zhu,Qi Wang,Ren-shan Ge,Zongfu Pan,Bo-wen Wu,Lijun Ge,Yihan Zhang,Yi-fan Wang,Guofang Shen,Danyan Zhu,Chun-sheng Xiang,Lanjuan Li,Yijia Lou

DOI: https://doi.org/10.1158/1940-6207.CAPR-15-0339

2016-01-01

Cancer Prevention Research

Abstract:Aristolochic acid I (AM) existing in plant drugs from Aristolochia species is an environmental human carcinogen associated with urothelial cancer. Although gene association network analysis demonstrated gene expression profile changes in the liver of human T253 knock-in mice after acute AAI exposure, to date, whether AM causes hepatic tumorigenesis is still not confirmed. Here, we show that hepatic premalignant alterations appeared in canines after a 10 -day AAI oral administration (3 mg/kg/day). We observed c-Myc oncoprotein and oncofeta] RNA-binding protein Lin28B overexpressions accompanied by cancer progenitor-like cell formation in the liver by AM exposure, Meanwhile, we found that forkhead box 01 (FOXO1) was robustly phosphorylated, thereby shuttling into the cytoplasm of hepatocytes. Furthermore, utilizing microarray and qRT-PCR analysis, we confirmed that microRNA expression significantly dysregulated hi the liver treated with AAI. Among them, we particularly focused on the members in let-7 miRNAs and rniR23a clusters, the downstream of c-Myc and 1L6 receptor (IL6R,611) signaling pathway linking the premalignant alteration. Strikingly, when IL6 was added in vitro, 11,614,/111NF-kappa B signaling activation contributed to the increase of FOXO1 phosphorylalion by the let -7b inhibitor. Therefore, it highlights the new insight into the interplay of the network in hepatic turnorigenesis by AA1 exposure, and also suggests that anti-premalignant therapy may be crucial for preventing AAI-induced hepatocarcinogenesis. Cancer Prev Res (C) 2016 AACR
Diagnosis and treatment of branchial cleft cysts and fistulae. A retrospective study of 183 patients.

Francisco C. Agaton-Bonilla,Cosme Gay-Escoda

DOI: https://doi.org/10.1016/S0901-5027(96)80081-6

1996-12-01

Abstract:
Cytotoxicity and genotoxicity of the carcinogen aristolochic acid I (AA-I) in human bladder RT4 cells

Medjda Bellamri,Kyle Brandt,Christina V Brown,Ming-Tsang Wu,Robert J Turesky

DOI: https://doi.org/10.1007/s00204-021-03059-3

Abstract:Aristolochic acid (AA-I) induces upper urothelial tract cancer (UUTC) and bladder cancer (BC) in humans. AA-I forms the 7-(2'-deoxyadenosin-N6-yl)aristolactam I (dA-AL-I) adduct, which induces multiple A:T-to-T:A transversion mutations in TP53 of AA-I exposed UTUC patients. This mutation is rarely reported in TP53 of other transitional cell carcinomas and thus recognized as an AA-I mutational signature. A:T-to-T:A transversion mutations were recently detected in bladder tumors of patients in Asia with known AA-I-exposure, implying that AA-I contributes to BC. Mechanistic studies on AA-I genotoxicity have not been reported in human bladder. In this study, we examined AA-I DNA adduct formation and mechanisms of toxicity in the human RT4 bladder cell line. The biological potencies of AA-I were compared to 4-aminobiphenyl, a recognized human bladder carcinogen, and several structurally related carcinogenic heterocyclic aromatic amines (HAA), which are present in urine of smokers and omnivores. AA-I (0.05-10 µM) induced a concentration- and time-dependent cytotoxicity. AA-I (100 nM) DNA adduct formation occurred at over a thousand higher levels than the principal DNA adducts formed with 4-ABP or HAAs (1 µM). dA-AL-I adduct formation was detected down to a 1 nM concentration. Studies with selective chemical inhibitors provided evidence that NQO1 is the major enzyme involved in AA-I bio-activation in RT4 cells, whereas CYP1A1, another enzyme implicated in AA-I toxicity, had a lesser role in bio-activation or detoxification of AA-I. AA-I DNA damage also induced genotoxic stress leading to p53-dependent apoptosis. These biochemical data support the human mutation data and a role for AA-I in BC.
The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation

Fiona K Middleton,John R Pollard,Nicola J Curtin

DOI: https://doi.org/10.3390/cancers10080275

2018-08-20

Abstract:Ataxia telangiectasia mutated and Rad3 related kinase (ATR) signals replication stress and DNA damage to S and G2 arrest and promotes DNA repair. Mutations in p53, critical for G1 checkpoint control, are common in cancer and predicted to confer vulnerability to ATR inhibitors. Reported data on the impact of p53 status are variable possibly because of the use of unmatched cells and surrogate endpoints of survival. The cytotoxicity of VE-821 alone and its ability to potentiate radiation and gemcitabine cytotoxicity was determined in isogenic and unmatched p53 wild-type (wt) and null/mutant cells, as well as immortalised nonmalignant MCF10 (immortalised non-neoplastic) cells, by colony-forming assay. The effect on cell cycle checkpoints was determined by flow cytometry. The isogenic p53 defective cells were not more sensitive to VE-821 alone. Defective p53 consistently conferred greater chemo- and radiosensitisation, particularly at high dose levels in isogenic cells but not unmatched cells. VE-821 did not sensitise MCF10 cells. We conclude that p53 status is just one factor contributing to chemo- and radiosensitisation by ATR inhibition, the lack of chemo- or radiosensitisation in the noncancerous cells suggests an element of tumour-specificity that warrants further investigation. The greater sensitisation at high-dose irradiation suggests that ATR inhibitors may be most effective with hypofractionated radiotherapy.
Induction of P450 1A by 3-methylcholanthrene protects mice from aristolochic acid-I-induced acute renal injury.

Xiang Xue,Ying Xiao,Hongli Zhu,Hui Wang,Yongzhen Liu,Tianpei Xie,Jin Ren

DOI: https://doi.org/10.1093/ndt/gfn262

IF: 7.1857

2008-01-01

Nephrology Dialysis Transplantation

Abstract:Background. Cytochrome P450 1A, an enzyme known to metabolize polycyclic aromatic hydrocarbons (PAHs), participates in the metabolism of aristolochic acid I (AAI) in liver and kidney microsomes isolated from humans and rodents. This study was designed to investigate whether P450 1A plays a role in AAI-induced renal injury in C57BL/6 mice. Methods. Separate groups of mice were given AAI (10 mg/kg and 20 mg/kg) or pretreatment with 3-methylcholanthrene (3-MC, an agent known to induce P450 1A expression in many species including rodents) at 60 mg/kg given at 24 h before AAI injection. Renal function and histopathology were determined at the 3rd day following the high dose of AAI and at the 14th day following the low dose of AAI treatment. For both doses, we determined in vivo AAI clearances and pharmacokinetic parameters. We also determined in vitro P450 1A1/2 activity and the ability of liver microsomes from 3-MC-treated and vehicle-treated mice to metabolize AAI. Finally, the effect of 3-MC on protein levels of P450 1A1/2 in both liver and kidney was measured by western blotting. Results. Pretreatment with 3-MC greatly protected mice against renal failure induced by AAI. In vivo AAI clearance was more rapid in 3-MC-pretreated mice than in the vehicle-pretreated mice. In addition, the P450 1A1/2 activity and the ability to metabolize AAI in hepatic microsomes isolated from 3-MC-treated mice were much greater than in vehicle-treated mice. Western blotting showed that protein levels of hepatic P450 1A1/2 were greatly increased in 3-MC-treated mice than in vehicle-treated mice. Conclusion. These results demonstrated that the induction of hepatic P450 1A1/2 protected against AAI-induced kidney injury through faster in vivo clearance of AAI and suggested an important role for hepatic P450s in the detoxification of AAI-induced renal injury.
Combinatorial Analytic Tableaux

R. Cowen

Abstract:
Tubular P53 Regulates Multiple Genes to Mediate AKI

Dongshan Zhang,Yu Liu,Qingqing Wei,Yuqing Huo,Kebin Liu,Fuyou Liu,Zheng Dong

DOI: https://doi.org/10.1681/asn.2013080902

IF: 14.978

2014-01-01

Journal of the American Society of Nephrology

Abstract:A pathogenic role of p53 in AKI was suggested a decade ago but remains controversial. Indeed, recent work indicates that inhibition of p53 protects against ischemic AKI in rats but exacerbates AKI in mice. One intriguing possibility is that p53 has cell type-specific roles in AKI. To determine the role of tubular p53, we generated two conditional gene knockout mouse models, in which p53 is specifically ablated from proximal tubules or other tubular segments, including distal tubules, loops of Henle, and medullary collecting ducts. Proximal tubule p53 knockout (PT-p53-KO) mice were resistant to ischemic and cisplatin nephrotoxic AKI, which was indicated by the analysis of renal function, histology, apoptosis, and inflammation. However, other tubular p53 knockout (OT-p53-KO) mice were sensitive to AKI. Mechanistically, AKI associated with the upregulation of several known p53 target genes, including Bax, p53-upregulated modulator of apoptosis-α, p21, and Siva, and this association was attenuated in PT-p53-KO mice. In global expression analysis, ischemic AKI induced 371 genes in wild-type kidney cortical tissues, but the induction of 31 of these genes was abrogated in PT-p53-KO tissues. These 31 genes included regulators of cell death, metabolism, signal transduction, oxidative stress, and mitochondria. These results suggest that p53 in proximal tubular cells promotes AKI, whereas p53 in other tubular cells does not.
Aristolochic acid I promoted clonal expansion but did not induce hepatocellular carcinoma in adult rats

Yong-zhen Liu,Heng-lei Lu,Xin-ming Qi,Guo-zhen Xing,Xin Wang,Pan Yu,Lu Liu,Fang-fang Yang,Xiao-lan Ding,Ze-an Zhang,Zhong-ping Deng,Li-kun Gong,Jin Ren

DOI: https://doi.org/10.1038/s41401-021-00622-7

IF: 7.169

2021-03-08

Acta Pharmacologica Sinica

Abstract:Aristolochic acid I (AAI) is a well-known nephrotoxic carcinogen, which is currently reported to be also associated with hepatocellular carcinoma (HCC). Whether AAI is a direct hepatocarcinogen remains controversial. In this study we investigated the association between AAI exposure and HCC in adult rats using a sensitive rat liver bioassay with several cofactors. Formation of glutathione S-transferase placental form-positive (GST-P+) foci was used as the marker for preneoplastic lesions/clonal expansion. We first conducted a medium-term (8 weeks) study to investigate whether AAI had any tumor-initiating or -promoting activity. Then a long-term (52 weeks) study was conducted to determine whether AAI can directly induce HCC. We showed that oral administration of single dose of AAI (20, 50, or 100 mg/kg) in combination with partial hepatectomy (PH) to stimulate liver proliferation did not induce typical GST-P+ foci in liver. In the 8-week study, only high dose of AAI (10 mg · kg−1 · d−1, 5 days a week for 6 weeks) in combination with PH significantly increased the number and area of GST-P+ foci initiated by diethylnitrosamine (DEN) in liver. Similarly, only high dose of AAI (10 mg· kg−1· d−1, 5 days a week for 52 weeks) in combination with PH significantly increased the number and area of hepatic GST-P+ foci in the 52-week study. No any nodules or HCC were observed in liver of any AAI-treated groups. In contrast, long-term administration of AAI (0.1, 1, 10 mg· kg−1· d−1) time- and dose-dependently caused death due to the occurrence of cancers in the forestomach, intestine, and/or kidney. Besides, AAI-DNA adducts accumulated in the forestomach, kidney, and liver in a time- and dose-dependent manner. Taken together, AAI promotes clonal expansion only in the high-dose group but did not induce any nodules or HCC in liver of adult rats till their deaths caused by cancers developed in the forestomach, intestine, and/or kidney. Findings from our animal studies will pave the way for further large-scale epidemiological investigation of the associations between AA and HCC.

pharmacology & pharmacy,chemistry, multidisciplinary
p53 mediates mitochondria dysfunction-triggered autophagy activation and cell death in rat striatum.

Xing-Ding Zhang,Ye Wang,Yan Wang,Xuan Zhang,Rong Han,Jun-Chao Wu,Zhong-Qin Liang,Zhen-Lun Gu,Feng Han,Kohji Fukunaga,Zheng-Hong Qin

DOI: https://doi.org/10.4161/auto.5.3.8174

IF: 13.391

2009-01-01

Autophagy

Abstract:In vivo administration of the mitochondrial inhibitor 3-nitropropionic acid (3-NP) produces striatal pathology mimicking Huntington disease (HD). However, the mechanisms of cell death induced by metabolic impairment are not fully understood. The present study investigated contributions of p53 signaling pathway to autophagy activation and cell death induced by 3-NP Rat striatum was intoxicated with 3-NP by stereotaxic injection. Morphological and biochemical analyses demonstrated activation of autophagy in striatal cells as evidenced by increased formation of autophagosomes, the expression of active lysosomal cathepsin B and D, microtubule associate protein light chain 3 (LC3) and conversion of LC3-I to LC3-II. 3-NP upregulated the expression of tumor suppressor protein 53 (p53) and its target genes including Bax, p53-upregulated modulator of apoptosis (PUMA) and damage-regulated autophagy modulator (DRAM). 3-NP-induced elevations in pro-apoptotic proteins Bax and PUMA, autophagic proteins LC3-II and DRAM were significantly reduced by the p53 specific inhibitor pifithrin-alpha (PFT). PFT also significantly inhibited 3-NP-induced striatal damage. Similarly, 3-NP-induced DNA fragmentation and striatal cell death were robustly attenuated by the autophagy inhibitor 3-methyladenine (3-MA) and bafilomycin A1 (BFA). These results suggest that p53 plays roles in signaling both autophagy and apoptosis. Autophagy, at least partially, contributes to neurodegeneration induced by mitochondria dysfunction.
Tumour Induction in Rats Following Exposure to Short-Term High Dose Aristolochic Acid I

M Cui,ZH Liu,Q Qiu,H Li,LS Li

DOI: https://doi.org/10.1093/mutage/gei007

2005-01-01

Mutagenesis

Abstract:The purpose of this study was to assess the carcinogenic activity of aristolochic acid I (AAI) in short-term high doses. Forty-four female Sprague-Dawley rats were randomly assigned to two groups. A dose of 50 mg/kg/day AAI was administrated to rats in the experimental group by gavage consecutively for 3 days, while the control group received only distilled water, after which renal function and pathological changes were assessed. At day 8 post-treatment AAI had induced elevations of both plasma urea and creatinine, coupled with increased urine production, urinary proteins, glucose and N-acetyl-beta-glucosaminidase. At 1, 3 and 6 months post-treatment renal function and urinary parameters for the experimental group approached baseline values. However, tumours and preneoplastic proliferation were both observed at 6 months for the experimental group. The rate of occurrence of preneoplastic proliferation in the kidneys was 100% (14/14); the rate of occurrence of renal tumours was 28.6% (4/14), which included three mesenchymal tumours and one case of renal oncocytoma; the rate of occurrence of extrarenal tumours was 7.1% (1/14), which was a case of mammary duct carcinoma. Renal preneoplastic proliferation and renal tumours, as well as extrarenal tumours, were not observed in control rats during the 6 months. These results differ from previous reports in that tumours originating from both epithelial and mesenchymal tissues were found, which may be attributed to the duration of treatment and the dosage of the drug. These data indicate that AAI administered in an acute manner at high doses does in fact have carcinogenic properties.
Differences in p38-STAT3-S100A11 signaling after the administration of aristolochic acid I and IVa may account for the disparity in their nephrotoxicity

Zhong Xian,Jingzhuo Tian,Yong Zhao,Yan Yi,Chunying Li,Jiayin Han,Yushi Zhang,Yuan Wang,Lianmei Wang,Suyan Liu,Chen Pan,Chenyue Liu,Dunfang Wang,Jing Meng,Xuan Tang,Fang Wang,Aihua Liang

DOI: https://doi.org/10.1016/j.phymed.2023.154815

IF: 6.656

2023-04-11

Phytomedicine

Abstract:Background The safety of herbs containing aristolochic acids (AAs) has become a widespread concern. Previous reports indicate that AAs are highly nephrotoxic and carcinogenic, although there are more than 170 analogues of aristolochic acid. Not all AAs have the same degree of nephrotoxicity or carcinogenicity. Previous studies have found that aristolochic acid IVa (AA-IVa), the principal component of AAs within members of the Aristolochiaceae family, especially Asarum , a commonly used herb in China, has essentially no significant nephrotoxicity. However, several studies, including ours, have shown that aristolochic acid I (AA-I) is clearly nephrotoxic. Purpose The focus of the study was to elucidate the molecular mechanism responsible for the difference in nephrotoxicity between the AA-I and AA-IVa. Study design/Method Mice were administered with AA-I or AA-IVa for 22 weeks through the oral route, followed by a 50-week recovery time. The kidney tissues of mice were extracted at the end of 22 weeks. Pathological examination and proteomic detection (tandem mass tagging (TMT) and phosphorylated proteomics) were performed on the kidney tissue to investigate the key signaling pathways and targets of AAs-induced renal interstitial fibrosis (RIF). The key signaling pathways and targets were verified by Western blot (WB), siRNA transfection, and luciferase assays. Results AA-I caused severe nephrotoxicity, high mortality, and extensive RIF. However, the same AA-IVa dosage exhibited almost no nephrotoxicity and does not trigger RIF. The activation of the p38-STAT3-S100A11 signaling pathway and upregulated expression of α smooth muscle actin (α-SMA) and Bcl2-associated agonist of cell death (Bad) proteins could be the molecular mechanism underlying AA-I-induced nephrotoxicity. On the other hand, AA-IVa did not regulate the activation of the p38-STAT3-S100A11 signaling pathway and had relatively little effect on the expression of α-SMA and Bad. Consequently, the difference in the regulation of p38-STAT3-S100A11 pathway, α-SMA, and Bad proteins between AA-I and AA-IVa may be responsible for the divergence in their level of nephrotoxicity. Conclusion This is the first study to reveal the molecular mechanism underlying the difference in nephrotoxicity between AA-I and AA-IVa. Whether STAT3 is activated or not may be the key factor leading to the difference in nephrotoxicity between AA-I and AA-IVa.

pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences
Regulation of PUMA- α by p53 in cisplatin-induced renal cell apoptosis

M Jiang,Q Wei,J Wang,Q Du,J Yu,L Zhang,Z Dong

DOI: https://doi.org/10.1038/sj.onc.1209440

IF: 8.756

2006-01-01

Oncogene

Abstract:Nephrotoxicity is a major side effect of cisplatin, a widely used cancer therapy drug. Depending on its concentration, cisplatin induces necrosis or apoptosis of tubular cells in the kidneys, whereas the underlying injury mechanism is unclear. Our recent work has suggested a critical role for p53 in cisplatin-induced tubular cell apoptosis; nevertheless, the apoptotic events triggered by p53 remain elusive. The current study has examined Bcl-2 family proteins, critical regulators of apoptosis that may be subjected to p53 regulation. Following cisplatin treatment, the expression of Bcl-xL, an antiapoptotic molecule, was suppressed, while the expression of Bak, a proapoptotic molecule, increased slightly. Of interest, PUMA- α , a newly identified p53-responsive proapoptotic Bcl-2 family protein, was drastically induced by cisplatin. PUMA- α induction preceded or paralleled the development of apoptosis. Induced PUMA- α was localized in mitochondria and appeared to antagonize Bcl-xL via molecular interaction. PUMA- α induction during cisplatin treatment was attenuated by pifithrin- α , a pharmacological inhibitor of p53, which was accompanied by the amelioration of Bax activation, cytochrome c release and apoptosis. Moreover, PUMA- α induction was suppressed by dominant-negative p53. Importantly, cisplatin-induced apoptosis was ameliorated in PUMA- α knockout cells. In vivo , cisplatin induced PUMA- α in the kidneys, and the inductive response was abrogated in p53-deficient animals. Together, this study has demonstrated the first compelling evidence for the involvement of PUMA- α in p53-mediated renal cell apoptosis during cisplatin nephrotoxicity.
Effects of Genetic Variation on Urinary Small Molecule Signatures of Mice after Exposure to Ionizing Radiation: A Study of p53 Deficiency

Evan L. Pannkuk,Evagelia C. Laiakis,Pelagie Ake,Steven J. Strawn,Yi-Wen Wang,Albert J. Fornace

DOI: https://doi.org/10.3390/metabo10060234

IF: 4.1

2020-06-08

Metabolites

Abstract:Due to risks from potential exposures to ionizing radiation (IR), improved radiological countermeasures are required, as well as rapid high-throughput biodosimetry. Genotypic variation in the general population contributes to differences in radiosensitivity that may affect biodosimetry accuracy. Previous studies utilized radiosensitive mutant mouse models (Parp1−/− and Atm−/−) to determine the effects of genotypic deficiency on radiation signatures. Here, we extend this approach by examining changes in the urinary metabolome in a hematopoietic (HP) resistant mouse model (p53−/−) after IR exposure. As p53 is a primary regulator in radiation response and apoptosis, limited hematopoietic stem cell apoptosis leads to reduced mortality at doses of ~8–10 Gy but increased mortality at higher doses (>15 Gy) due to mitotic catastrophe in gastrointestinal (GI) crypt cells. Urine was collected from mice (wild-type (WT), p53+/−, and p53−/−) pre-irradiation and at 4 and 24 h after total body irradiation (TBI) (WT: 8 and 10 Gy; p53−/−: 10 Gy) for metabolic phenotyping using an ultra-performance liquid chromatography mass spectrometry (UPLC-MS) platform. Minimal differences were detected between unirradiated WT, p53+/−, and p53−/− mice. While similar perturbations were observed for metabolites involved in tryptophan, vitamin B6, and histamine pathways, glycine conjugation, and redox metabolism for WT and p53−/− mice after TBI, an overall dampened response was observed in p53-deficient mice. Despite comparable metabolite patterns between genotypes, differentiation was achieved through receiver operating characteristic curve analysis with high specificity and sensitivity for carnitine, N1-acetylspermidine, and creatine. These studies highlight that both attenuated and dampened metabolic responses due to genetic variability in the general population need to be addressed in biodosimetry frameworks.

biochemistry & molecular biology
Stomatal function in relation to leaf metabolism and environment.

I. R. Cowan,G. Farquhar

Abstract:

A testing strategy to evaluate the mutagenic activity of industrial chemicals in cultured mammalian cells.

Activation of P53 Promotes Renal Injury in Acute Aristolochic Acid Nephropathy.

The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53(+/+), Trp53(+/-) and Trp53(-/-) mice

Study on DNA Damage Induced by Aristolochic Acid in Vitro

Agglutination with con A dependent on cell cycle.

Aristolochic acid I induce DNA damage and cell cycle arrest in proximal tubule epithelium cell

Aristolochic Acid I-induced DNA Damage and Cell Cycle Arrest in Renal Tubular Epithelial Cells in Vitro

Hepatic Premalignant Alterations Triggered by Human Nephrotoxin Aristolochic Acid I in Canines

Diagnosis and treatment of branchial cleft cysts and fistulae. A retrospective study of 183 patients.

Cytotoxicity and genotoxicity of the carcinogen aristolochic acid I (AA-I) in human bladder RT4 cells

The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation

Induction of P450 1A by 3-methylcholanthrene protects mice from aristolochic acid-I-induced acute renal injury.

Combinatorial Analytic Tableaux

Tubular P53 Regulates Multiple Genes to Mediate AKI

Aristolochic acid I promoted clonal expansion but did not induce hepatocellular carcinoma in adult rats

p53 mediates mitochondria dysfunction-triggered autophagy activation and cell death in rat striatum.

Tumour Induction in Rats Following Exposure to Short-Term High Dose Aristolochic Acid I

Differences in p38-STAT3-S100A11 signaling after the administration of aristolochic acid I and IVa may account for the disparity in their nephrotoxicity

Regulation of PUMA- α by p53 in cisplatin-induced renal cell apoptosis

Effects of Genetic Variation on Urinary Small Molecule Signatures of Mice after Exposure to Ionizing Radiation: A Study of p53 Deficiency

Stomatal function in relation to leaf metabolism and environment.